CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The project aims to develop ex vivo organoids that replicate the tumor microenvironment of activated B cell diffuse large B-cell lymphoma. By mimicking the interactions between immune cells and the extracellular matrix, the project seeks to understand how these factors influence the survival of cancer cells and their r…
Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL) in Europe and worldwide with more than 463/100 000/year.
Activated B cell (ABC)-DLBCL represents the more aggressive and chemo-resistant subtype to the frontline therapy Rituximab (R)-CHOP (doxorubicin, vincristine, prednisone, mechlorethamine) with 40% of patients experiencing no response or relapse.
Therefore, new treatments are needed to improve the clinical outcome of ABC-DLBCLs. A newly defined char…
EBERHARD KARLS UNIVERSITAET TUEBINGEN
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
United States, Atlanta
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
